Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer

Urology

Volumn 47, Issue 5, 1996, Pages 708-712

  Gleave, Martin E ^a,b   Coupland, David ^a   Drachenberg, Darrel ^a   Cohen, Leslie ^a   Kwong, Stephen ^a   Goldenberg, S Larry ^a   Sullivan, Lorne D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY;

EID: 0029896601     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)80016-1     Document Type: Article

References (11)

1. Murphy GP, Natarajan N, Pontes JE, Schmitz RI, Smart CR, Schmidt JD, and Mettlin C: The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 127: 928-934, 1982.
2. Veterans Administration Cooperative Urologic Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011-1017, 1967.
3. Boring CC, Squires TS, Tong T, and Montgomery S: Cancer statistics, 1994. CA Cancer J Clin 44: 7-26, 1994
4. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, and Lange PH: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147: 841-845, 1992
5. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Tuan JJ, Petros JA, and Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161, 1991.
6. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, and Redwine E: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
7. Gleave M. Hsieh JT, Wu HC, von Eschenbach AC, and Chung LW: Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 52: 1598-1605, 1992.
8. Andriole GL, and Catalona WJ. Using PSA to screen for prostate cancer. The Washington University experience. Urol Clin North Am 20: 647-651, 1993.
9. Schaffer DL, and Pendergrass HP: Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 121: 431-434, 1976.
10. Oesterling JE, Martin SK, Bergstralh EJ, and Lowe FC: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269: 57-60, 1993.
11. Chybowski FM, Keller JJ, Bergstralh EJ, and Oesterling JE: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 145: 313-318, 1991.